Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Keywords:
Materias Investigacion::Ciencias de la Salud
Nivolumab
Sorafenib
Hepatocellular carcinoma
Publisher:
Lancet Pub. Group
Citation:
Yau, T. (Thomas); Park, J.W. (Joong-Won); Finn, R.S. (Richard S.); et al. "Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial". The Lancet. Oncology. 23 (1), 2022, 77 - 90
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.